Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan(®) Databases

por Leonardi, Craig, Zhu, Baojin, Malatestinic, William N., Eastman, William J., Guo, Jiaying, Murage, Mwangi J., Choong, Casey Kar-Chan, Burge, Russel, Blauvelt, Andrew
Publicado 2022

Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months

por Blauvelt, Andrew, Shi, Nianwen, Burge, Russel, Atiya, Bilal, Zhu, Baojin, Somani, Najwa, Ridenour, Terri, Lew, Carolyn R., Zimmerman, Nicole M., Murage, Mwangi J.
Publicado 2022

Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months

por Blauvelt, Andrew, Shi, Nianwen, Burge, Russel, Somani, Najwa, Ridenour, Terri L., Zhu, Baojin, Atiya, Bilal, Lew, Carolyn R., Zimmerman, Nicole M., Murage, Mwangi J.
Publicado 2021

Real‐World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study

por Murage, Mwangi J., Princic, Nicole, Park, Julie, Malatestinic, William, Zhu, Baojin, Atiya, Bilal, Kern, Scott A., Stenger, Keri B., Sprabery, Aubrey Trevelin, Ogdie, Alexis
Publicado 2021

Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs

por Murage, Mwangi J, Princic, Nicole, Park, Julie, Malatestinic, William N, Zhu, Baojin, Atiya, Bilal, Kern, Scott A, Stenger, Keri B, Sprabery, Aubrey Trevelin, Ogdie, Alexis
Publicado 2022

Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab

por Blauvelt, Andrew, Shi, Nianwen, Burge, Russel, Malatestinic, William N, Lin, Chen-Yen, Lew, Carolyn R, Zimmerman, Nicole M, Goldblum, Orin M, Zhu, Baojin, Murage, Mwangi J
Publicado 2020

Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry

por Lockshin, Benjamin, Harrison, Ryan W., McLean, Robert R., Crabtree, Margaux M., Konicek, Bruce W., Zhu, Baojin, Malatestinic, William N., Atiya, Bilal, Murage, Mwangi J., Burge, Russel T.
Publicado 2022

Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review

por Murage, Mwangi J, Tongbram, Vanita, Feldman, Steven R, Malatestinic, William N, Larmore, Cynthia J, Muram, Talia M, Burge, Russel T, Bay, Charles, Johnson, Nicole, Clifford, Sarah, Araujo, Andre B
Publicado 2018

Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry

por Lockshin, Benjamin, Cronin, Angel, Harrison, Ryan W., McLean, Robert R., Anatale‐Tardiff, Laura, Burge, Russel, Zhu, Baojin, Malatestinic, William N., Atiya, Bilal, Murage, Mwangi J., Gallo, Gaia, Strober, Bruce, Van Voorhees, Abby
Publicado 2021